Call to Entrepreneurs and Start-ups! Integral BioSystems Offers Rapid Testing Services

Drug delivery firm Integral BioSystems announces fast-track, rapid-development services for start-up companies, fledging companies and entrepreneurs!



Integral BioSystems Logo

BEDFORD, MA, UNITED STATES, September 6, 2026 /EINPresswire.com/ -- Bedford, MA – Sept 5, 2026 – Integral BioSystems LLC, Boston area drug delivery CRO has multi-tiered experience in all phases of Chemistry, Manufacturing and Controls-related drug development for small molecules, proteins and gene therapies. Since its inception in 2009, the company has gained credibility in developing numerous drug compositions in areas of ophthalmology, dermatology, intranasal, otic and injectables.

> “No job is too small or too large for Integral BioSystems to give its undivided attention.”
>
> *Shikha Barman CEO*

In light of the current uncertainty in the accessibility of startup investment funds to enable groundbreaking research into proof-of-concept testing in the clinic, Integral BioSystems is offering fast-track packages to startups and fledging companies to rapidly develop analytical methods and formulation compositions to obtain additional preclinical assurance of their concepts. We have already aided and advised numerous companies to meet their development goals; quite a few of these companies have completed or, are planning proof-of-concept clinical studies.

Integral BioSystems scientists collectively have decades of experience in the design of sustained release injectables, such as microspheres with encapsulated DNA, proteins or small molecules. Due to more than a decade in business, the company owns turn-key methods for residual solvent and moisture analysis, and state-of-the-art equipment to perform spray-drying, lyophilized, or suspension products.

Integral invites all companies operating on a shoe-string budget, to discuss their programs. With over 30 years of experience in all phases of tissue targeted, sustained release pharmaceutical formulation development, the firm’s founder, President and CEO Dr. Shikha P. Barman, and company R&D Head Kevin Ward, are happy to discuss all projects, no matter how early-stage.

Integral also offers turn-key testing services such as particle sizing and stability testing.

Integral is here to help.

ABOUT INTEGRAL BIOSYSTEMS
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.

The Company has developed numerous dosage forms. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes. The company offers rapid proof-of-concept feasibility formulations or development toward IND submission, including cGLP services.

Dave Karasic, Esq.
Chief Operations Officer
Integral BioSystems LLC
dkarasic@integralbiosystems.com

Dave Karasic
Integral BioSystems, LLC
+1 617-820-8483
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/940029834

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.